Q4 2024 Earnings Call Transcript February 12, 2025 Ascendis Pharma A/S beats earnings expectations. Reported EPS is $-0.68699 ...

When patients can’t access their MHT patches, they may consider switching to different formulations, such as tablets or gels.

So far this month, the Georgia Senate has passed two bills adding new restrictions on transgender Georgians, and they could ...

Q4 2024 Earnings Conference Call February 13, 2025 8:30 AM ETCompany ParticipantsJennifer Halchak - VP, IRKevin Ali - ...

Pfizer Inc. today announced positive results from the Phase 3 TALAPRO-2 study of TALZENNA® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with XTANDI® (enzalutamide ...

The National Medical Commission (NMC) has issued Guidelines for the competency-based postgraduate training programme for MCh ...